1. Nanosystems, Drug Molecule Functionalization and Intranasal Delivery: An Update on the Most Promising Strategies for Increasing the Therapeutic Efficacy of Antidepressant and Anxiolytic Drugs
   Jéssica L. Antunes et al, 2023, Pharmaceutics CrossRef
2. Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review
   Octavian Vasiliu, 2023, Exp Ther Med CrossRef
3. Baseline characteristics of a European patient population with difficult-to-treat depression (RESTORE-LIFE) treated with adjunctive vagus nerve stimulation
   Koen Demyttenaere et al, 2024, Journal of Affective Disorders CrossRef
4. Preclinical models of treatment-resistant depression: challenges and perspectives
   Magdalena Kolasa et al, 2023, Pharmacol. Rep CrossRef
5. Illuminating the way: the role of bright light therapy in the treatment of depression
   Biljana Kosanovic Rajacic et al, 2023, Expert Review of Neurotherapeutics CrossRef
6. Effect of single intravenous injection of esketamine on postpartum depression after labor analgesia and potential mechanisms: a randomized, double-blinded controlled trial
   Bin Ling et al, 2023, BMC Pharmacol Toxicol CrossRef
7. Overcoming treatment gaps in the management of depression with non-pharmacological adjunctive strategies
   György Purebl et al, 2023, Front. Psychiatry CrossRef
8. The “new wave” of antidepressants: are these agents paradigm-shifters in treating major depression?
   B. Petrescu et al, 2023, Psihiatru.ro CrossRef
9. Ketamine and Nitrous Oxide
   Alvin M. Janski et al, 2024 CrossRef
10. The Psychiatric, Psychological, and Psychotherapeutic Approach to Erectile Dysfunction – Between Good Practices and Clinical Challenges
    Octavian Vasiliu et al, 2024, RJMM CrossRef
11. Impact of Adjunctive VNS on Drug Load, Depression Severity, and Number of Neuromodulatory Maintenance Treatments
    Erhan Kavakbasi et al, 2024, Brain Sciences CrossRef
12. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review
    Suneeta Kumari et al, 2024 CrossRef
13. New Light on Prions: Putative Role of PrPc in Pathophysiology of Mood Disorders
    Adrian Andrzej Chrobak et al, 2024, IJMS CrossRef
14. Supplemental low-dose esketamine to propofol versus propofol alone on perioperative characteristics in children undergoing surgery: a prospective randomized controlled trial
    Ding HAN et al, 2024, Minerva Anestesiol CrossRef
15. Unlocking new avenues for neuropsychiatric disease therapy: the emerging potential of Peroxisome proliferator-activated receptors as promising therapeutic targets
    Asmita Deka Dey et al, 2024, Psychopharmacology CrossRef
16. The cyclical revival of psychedelics in psychiatric treatment
    FranciscoJ. Appiani et al, 2024, Current Medical Research and Opinion CrossRef
17. Perioperative esketamine administration for prevention of postpartum depression after the cesarean section: A systematic review and meta-analysis
    Mohammadamin Parsaei et al, 2024, Journal of Affective Disorders CrossRef
18. Exploring the Comorbidity, Pathophysiology, and Integrated Treatment Strategies of Hypertension and Depression
    Nicholas A. Kerna et al, 2024, ejmhr CrossRef
19. Research Progress of Esketamine in Improving Perioperative Depression and Sleep Quality
    永旭 高, 2024, ACM CrossRef
20. Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder
    Joseph Blanco et al, 2024, Expert Review of Neurotherapeutics CrossRef
21. Psychometric properties of the 23-Item Clinician Administered Dissociative States Scale (CADSS) in a psychological trauma population
    J. Douglas Bremner et al, 2024, Journal of Affective Disorders CrossRef
22. CETAMINA COMO INTERVENÇÃO TERAPÊUTICA NA DEPRESSÃO PSICÓTICA E DEPRESSÃO REFRATÁRIA A TRATAMENTO
    Pedro Peixoto dos Santos et al, 2024, RECIMA21 CrossRef
23. Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD)
    Berend Olivier et al, 2024 CrossRef
24. Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms
    Piotr Kawczak et al, 2024, Biomedicines CrossRef
25. Treatment-resistant depression
    Leesa A. McBroom et al, 2024 CrossRef
26. Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review
    Simone Pardossi et al, 2024, IJMS CrossRef
27. Activation of glutamine synthetase (GS) as a new strategy for the treatment of major depressive disorder and other GS-related diseases
    Jae Soon Kang et al, 2025, Acta Pharmacol Sin CrossRef